PhaseV Launches AI-Powered Enrollment Lab

Why It Matters

Evidence‑based enrollment forecasts reduce trial delays and improve success rates, giving sponsors a competitive edge in drug development.

Key Takeaways

• AI Enrollment Lab quantifies enrollment potential using real-world EHR data
• Tool models patient competition and eligibility before protocol lock
• Enables sponsors to stress‑test protocol designs and optimize criteria
• Identifies untapped geographic regions and low‑competition patient segments
• Integrates with ClinOps for seamless site identification workflow

Pulse Analysis

Clinical trial enrollment has long been a bottleneck, with sponsors relying on site surveys and historical benchmarks that often misjudge patient availability. The rise of AI and access to large-scale electronic health records is reshaping this landscape, allowing developers to move from guesswork to data‑driven projections. By tapping into anonymized, real‑world patient data, platforms can now simulate how many eligible participants exist across regions and how competing studies affect access, delivering a granular view of enrollment feasibility.

PhaseV's Enrollment Lab builds on this paradigm shift, embedding AI algorithms directly into its ClinOps suite. The system cross‑references trial inclusion and exclusion criteria with live EHR datasets, then overlays competitive trial activity to calculate realistic patient pools. Users can instantly adjust protocol parameters—such as age ranges or biomarker thresholds—and see the immediate impact on enrollment volume. This iterative, evidence‑based approach helps sponsors identify hidden geographic pockets and low‑competition patient segments, streamlining site selection and reducing the risk of under‑enrollment.

For the broader biotech and pharma ecosystem, tools like the Enrollment Lab signal a move toward precision trial design. Faster, more accurate enrollment forecasts shorten development timelines, lower costs, and accelerate time‑to‑market for new therapies. As regulators and investors increasingly demand data‑backed trial plans, AI‑driven enrollment modeling is poised to become a standard component of clinical operations, driving efficiency and improving patient access to innovative treatments.